COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations

Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: imm...

Descripción completa

Detalles Bibliográficos
Autores: Jutel, M, Torres, MJ, Palomares, O, Akdis, CA, Eiwegger, T, Untersmayr, E, Barber, D, Zemelka-Wiacek, M, Kosowska, A, Palmer, E, Vieths, S, Mahler, V, Canonica, WG, Nadeau, K, Shamji, MH, Agache, I, Akdis, M, Khaitov, M, Alvarez-Perea, A, Alvaro-Lozano, M, Atanaskovic-Markovic, M, Backer, V, Barbaud, A, Bavbek, S, de Blay, F, Bonini, M, Bonini, S, van Boven, JFM, Brockow, K, Cazzola, M, Chatzipetrou, A, Chivato, T, Cianferoni, A, Corren, J, Cristoph-Caubet, J, Dunn-Galvin, A, Ebisawa, M, Firinu, D, Gawlik, R, Gelincik, A, del Giacco, S, Mortz, CG, Hoffmann, HJ, Hoffmann-Sommergruber, K, Klimek, L, Knol, E, Lauerma, A, de Llano, LP, Matucci, A, Meyer, R, Moreira, A, Morita, H, Patil, SU, Pfaar, O, Popescu, FD, del Pozo, V, Price, OJ, van Ree, R, Fernandez-Rivas, M, Rogala, B, Romano, A, Santos, A, Sediva, A, Skypala, I, Smolinska, S, Sokolowska, M, Sturm, G, Vultaggio, A, Walusiak-Skorupa, J, Worm, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p21368
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21368
Access Level:acceso abierto
Palabra clave:allergen
allergy
biologicals
Covid-19
immunotherapy
mRNA vaccines
Descripción
Sumario:Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.

Similares en LA Referencia